EGFR and neoplasm: An experiment [74] demonstrated that cetuximab (IgG1 monoclonal antibody against EGFR) and bevacizumab (IgG1 monoclonal antibody against VEGF) alone or in combination inhibited tumor cell growth and angiogenesis in in vivo models of ATC.